Efficacy and safety of neoadjuvant chemoradiation therapy administered for 5 versus 2 weeks for resectable and borderline resectable pancreatic cancer

• Material Type: 博士論文
• Title: Efficacy and safety of neoadjuvant chemoradiation therapy administered for 5 versus 2 weeks for resectable and borderline resectable pancreatic cancer
• Author/Editor: 須藤, 広誠
• Author Heading: 須藤, 広誠
• Publication Date: 2022-09-30
• Publication Date (W3CDTF): 2022-09-30
• Degree grantor/type: 香川大学
• Date Granted: 2022-09-30
• Date Granted (W3CDTF): 2022-09-30
• Dissertation Number: 甲第815号
• Degree Type: 博士（医学）
• Conferring No. (Dissertation): 甲第815号
• Text Language Code: eng
• Alias of Author: Suto, Hironobu
• Subject Heading: neoadjuvant therapy; pancreatic cancer; chemotherapy; chemoradiation; pancreatectomy
• Target Audience: 一般
• Note (General): Objectives: Indications of preoperative treatment for resectable (R-) or borderline resectable (BR-) pancreatic ductal adenocarcinoma (PDAC) are unclear, and the protocol remains to be standardized.; Methods: Included 65 patients with R- and BR-PDAC with venous involvement (V-) received neoadjuvant chemoradiotherapy with S-1 and 50 Gy of radiation as the 5-week regimen. The outcomes of this group were compared with those of 52 patients who underwent S-1 and 30 Gy of radiation as the 2-week regimen, previously collected as our prospective phase II study.; Results: Compared with the 2-week regimen, there were no significant differences in the rate of protocol completion, adverse events, mortality and morbidity, or R0 resection in the 5-week regimen. In subgroup analyses of R-PDAC, there were no significant differences in overall survival and recurrence-free survival between the groups. In contrast, the 5-week regimen had significantly better overall survival and recurrence-free survival than the 2-week regimen for BRV-PDAC. Similar results were observed after propensity score matching analysis.; Conclusions: The 5-week regimen of neoadjuvant chemoradiotherapy has good clinical efficacy and safety for R- and BRV-PDAC. The 5-week regimen could achieve better outcomes than the 2-week regimen for BRV-PDAC. In contrast, both regimens achieved similar outcomes for R-PDAC.
• DOI: info:doi/10.1097/MPA.0000000000002011; https://doi.org/info:doi/10.1097/MPA.0000000000002011
• Persistent ID (NDL): info:ndljp/pid/12361217; https://dl.ndl.go.jp/pid/12361217
• Collection: 障害者向け資料
• Collection (Materials For Handicapped People:1): テキストデータ
• Collection (particular): 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文; https://dl.ndl.go.jp/collections/A00014
• Acquisition Basis: 博士論文（自動収集）
• Date Accepted (W3CDTF): 2022-11-07T16:56:35+09:00
• Date Created (W3CDTF): 2022-10-18
• Format (IMT): その他形式; PDF; application/pdf
• Access Restrictions: 国立国会図書館内限定公開
• Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
• Availability of remote photoduplication service: 可
• Periodical Title (URI): https://kagawa-u.repo.nii.ac.jp/records/11465
• Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp

Table of Contents

2023-03-02 再収集